VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01655589
Recruitment Status : Unknown
Verified July 2012 by Institute of Vision, Brasil.
Recruitment status was:  Recruiting
First Posted : August 2, 2012
Last Update Posted : August 2, 2012
Information provided by (Responsible Party):
Institute of Vision, Brasil

Brief Summary:
The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

Condition or disease
Macular Degeneration

Study Type : Observational
Estimated Enrollment : 74 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration
Study Start Date : January 2008

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eye clinic in Belo Horizonte, Brazil

Inclusion Criteria:

  • Diagnosis of neovascular age-related macular degeneration
  • Visual acuity better than 20/400
  • Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
  • Follow-up period of at least six months

Exclusion Criteria:

  • Choroidal neovascularization secondary to any other cause than age-related macular degeneration
  • Eyes with polypoidal choroidal vasculopathy
  • Eyes previously submitted to posterior vitrectomy
  • Other diseases that could affect visual acuity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01655589

Institute of Vision Recruiting
Belo Horizonte, MG, Brazil, 30150270
Contact: Andre B Ferreira    55 31 32743355   
Sponsors and Collaborators
Institute of Vision, Brasil

Responsible Party: Institute of Vision, Brasil Identifier: NCT01655589     History of Changes
Other Study ID Numbers: IV-01
First Posted: August 2, 2012    Key Record Dates
Last Update Posted: August 2, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents